Clinical characteristics and outcomes in pulmonary manifestations of systemic sclerosis: Contribution from pulmonary hypertension and interstitial lung disease severity
Open Access
- 1 October 2022
- journal article
- research article
- Published by Wiley in Pulmonary Circulation
- Vol. 12 (4) , e12117
Abstract
Patients with systemic sclerosis complicated by both pulmonary hypertension (SSc‐PH) and interstitial lung disease (SSc‐PH‐ILD) have poor prognosis compared to those with SSc‐PH or SSc‐ILD alone. Little is known of how ILD severity affects outcomes in those with SSc‐PH, or how PH severity affects outcomes in those with SSc‐ILD. Herein, we aimed to delineate clinical features of patients with SSc‐PH and SSc‐ILD and determine to what degree PH and ILD severity contribute to mortality in patients with SSc. We conducted parallel retrospective studies in cohorts of patients with SSc‐PH and SSc‐ILD. We categorized ILD severity by pulmonary function testing and PH severity by cardiopulmonary hemodynamics. Our primary outcome was all‐cause mortality from time of PH or ILD diagnosis for the SSc‐PH and SSc‐ILD cohorts, respectively. We calculated adjusted risks of time to all‐cause mortality using Cox proportional hazards models. In patients with SSc‐PH, severe ILD (HR: 3.54; 95% CI: 1.05, 11.99) was associated with increased hazards for all‐cause mortality. By contrast, mild and moderate ILD were not associated with increased mortality risk. In patients with SSc‐ILD, both moderate (HR: 2.65; 95% CI: 1.12, 6.31) and severe PH (HR: 6.60; 95% CI: 2.98, 14.61) were associated with increased hazards for all‐cause mortality, while mild PH was not. Through our parallel study design, the risk of all‐cause mortality increases as severity of concomitant ILD or PH worsens. Therapies that target slowing disease progression earlier in the disease course may be beneficial.Keywords
Funding Information
- Rheumatology Research Foundation
- Health Resources and Services Administration (U1EMC27864‐08‐00)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (CCCR P30 AR072571)
- Novartis
- Bayer
- National Center for Advancing Translational Sciences (2UL1TR001430‐05A1)
- National Heart, Lung, and Blood Institute (1F32HL156614‐01, 1UG3HL143192‐01A1, 5F32HL149236‐02)
This publication has 22 references indexed in Scilit:
- Systemic sclerosis–related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapiesArthritis & Rheumatism, 2011
- Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosisAnnals of the Rheumatic Diseases, 2010
- Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathyEuropean Respiratory Journal, 2009
- Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung diseaseArthritis & Rheumatism, 2009
- Changes in causes of death in systemic sclerosis, 1972–2002Annals of the Rheumatic Diseases, 2007
- Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group databaseAnnals of the Rheumatic Diseases, 2007
- Cyclophosphamide versus Placebo in Scleroderma Lung DiseaseNew England Journal of Medicine, 2006
- Systemic sclerosis: hypothesis-driven treatment strategiesThe Lancet, 2006
- Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary FibrosisChest, 2006
- Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approachAnnals of the Rheumatic Diseases, 2003